{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-22-001470","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.040241+00:00","generated_at":"2026-06-22T14:53:43.379574+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcturus signs $200M upfront collaboration with CSL Seqirus for self-amplifying mRNA vaccines","bullets":["Arcturus receives $200M upfront; eligible for >$1.3B development and >$3B commercial milestones.","40% net profit share on COVID-19 vaccines; up to double-digit royalties on flu, pandemic, and 3 other respiratory vaccines.","Collaboration covers self-amplifying mRNA vaccines for COVID-19, influenza, pandemic preparedness, and three other respiratory diseases.","CSL Seqirus leads development and commercialization; Arcturus provides STARR technology and LUNAR delivery platform.","Transaction subject to HSR Act waiting period; J.P. Morgan advised Arcturus."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-22-001470","json":"https://secwatch.observer/filing/0001193805-22-001470.json","markdown":"https://secwatch.observer/filing/0001193805-22-001470.md","text":"https://secwatch.observer/filing/0001193805-22-001470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001470/0001193805-22-001470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001470/e617985_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:53:43.379574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"131a5e6736e590ad0156f9aed73f2de492db4bbe","claim":"Arcturus Therapeutics Holdings Inc. entered into Collaboration and License Agreement with CSL Seqirus, Inc. valued at Up-front payment of $200 million; development milestones totaling more than $1.3 billion; commercial (effective 2022-11-01).","evidence_excerpt":"On November 1, 2022, Arcturus Therapeutics Holdings Inc. (\"Arcturus\") entered into a Collaboration and License Agreement (the \"Collaboration Agreement\") with CSL Seqirus, Inc., a part of CSL Limited (\"CSL Seqirus\"), one of the world’s leading influenza vaccine providers, for the research, development, manufacture and global commercialization of self-amplifying mRNA vaccines.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001470/0001193805-22-001470-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"CSL Seqirus, Inc."},{"label":"Value","value":"Up-front payment of $200 million; development milestones totaling more than $1.3 billion; commercial"},{"label":"Effective","value":"2022-11-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}